Ongoing Spending on R&D Activities
First written in FY2017-Q2. 16 of 33 entries say "Restated". Latest entry: FY2026.
30 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Company newly developed a beverage containing lactose-fructose oligosaccharide and Sicilian lemon juice and launched it as the new product "Beets no Okage."」
As an R&D achievement, the Company developed and launched a new product using lactose-fructose oligosaccharide and Sicilian lemon juice. Total R&D expenses were ¥49 million. - 2026-05-08AdvancedManagement Planning
「中期経営計画5か年で成長投資・研究開発に25〜45億円を投じM&Aを含むインオーガニックな成長により、第3の収益柱の確立を目指す」
研究開発の継続支出という構造的事実から、5年間の成長投資・研究開発額とM&Aを含む第三の収益柱確立を伴う投資方針へ具体化している。 - FY2026-H1Slight decrease in R&D expensesAnnual report
「The Group's total R&D activities for the interim consolidated accounting period was ¥20 million.」
Although there were no material changes in the status of R&D activities, R&D expenses decreased from ¥21 million in the interim period of the previous year to ¥20 million. - FY2025AdvancedAnnual report
「The Company developed and launched Sugarcane Oligo, made from sugar derived from sugarcane.」
The Company reported the specific achievement of developing and launching Sugarcane Oligo, made from sugar derived from sugarcane, as an R&D project. - FY2025-H1Increase in R&D expensesAnnual report
「The Group's total R&D activities for the interim consolidated accounting period was ¥21 million.」
R&D activities continued, bringing total R&D expenses for the interim cumulative period to ¥21 million. - FY2024-Q2Decline in R&D ExpensesAnnual report
「The Group's total R&D activities for the second quarter cumulative period was ¥17 million.」
Although there were no material changes in the status of R&D activities, total R&D expenses decreased from ¥20 million in the same cumulative period of the previous year to ¥17 million. - FY2024-Q1Decline in R&D ExpensesAnnual report
「The Group's total R&D activities for the first quarter cumulative period was ¥7 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
Although there were no material changes in the status of R&D activities, total R&D expenses decreased from ¥11 million in the same cumulative period of the previous year to ¥7 million. - FY2023Research themes continued and R&D expenses decreasedAnnual report
「For research and development, the Company continued research into new functions of galacto-oligosaccharide, primarily through joint research, and studied the establishment of a more efficient production structure in cooperation with the business division.」
Research on functional foods with oligosaccharides, beets, cyclodextrin and sugar as the main ingredients continued, bringing total R&D expenses to ¥44 million. - FY2023-Q3Decline in R&D ExpensesAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥30 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
While stating that there were no material changes in the status of research and development activities, the Company reported that total R&D expenses decreased from ¥40 million in the same cumulative period of the previous year to ¥30 million. - FY2023-Q2Decline in R&D ExpensesAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥20 million.」
While stating that there were no material changes in the status of research and development activities, the Company reported that total R&D expenses decreased from ¥29 million in the same cumulative period of the previous year to ¥20 million. - FY2023-Q1Decline in R&D ExpensesAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥11 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
While stating that there were no material changes in the status of research and development activities, the Company reported total research and development activity spending of ¥11 million. - FY2022Research themes continued and R&D spending decreasedAnnual report
「For galacto-oligosaccharide, the Company continued research into new functions, primarily through joint research, and studied the establishment of a more efficient production structure in cooperation with the business division.」
The Company continued research into new functions of oligosaccharides, an efficient production structure, evaluation of the functionality of beets, and development of foods with function claims centered on sugar. Total R&D expenses amounted to ¥52 million. - FY2022-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥40 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
Research and development activities continued, and it was stated that there were no material changes in their status. - FY2022-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥29 million. There were no material changes in the status of the Group's research and development activities during the six-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2022-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥15 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2021Relocation of the research institute and continued beet researchAnnual report
「To establish an efficient R&D structure in cooperation with the business and sales divisions, the Company relocated its Carbohydrate Research Institute from Yokohama to its head office. For galacto-oligosaccharide, it continued research into new functions, primarily through joint research, while for beets, it conducted clinical research on the functionality of beet drinks and worked to develop new products containing beets. The total amount of R&D expenses for the consolidated fiscal year was ¥92 million.」
The Company relocated the Carbohydrate Research Institute to its head office, conducted research into new functions of oligosaccharides, and carried out clinical research and new product development for beet drinks, while R&D expenses amounted to ¥92 million. - FY2021-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥75 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2021-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥44 million. There were no material changes in the status of the Group's research and development activities during the six-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2021-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥25 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2020Research themes expanded and R&D expenses increasedAnnual report
「In addition to continuing research into new functions and cost reduction through a new production method for galacto-oligosaccharide, the Company worked to develop high-value-added products by studying the functionality labeling of beets, which has attracted attention as a superfood, and the physiological functions of sugar in combination with functional ingredients, with the aim of expanding new sales channels. The total amount of R&D expenses for the consolidated fiscal year was ¥100 million.」
In addition to a new production method and research into new functions for oligosaccharides, the R&D themes expanded to include functionality labeling for beets and high-value-added products combining sugar with functional ingredients, and R&D expenses amounted to ¥100 million. - FY2020-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥76 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2020-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥53 million. There were no material changes in the status of the Group's research and development activities during the six-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2020-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥29 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2019Research themes continued and R&D expenses increasedAnnual report
「The Company worked on reducing costs through a new production method for galacto-oligosaccharide, conducting R&D on its effects in improving the intestinal environment and its new functions, and developing new products that add new functions to existing products. The total amount of R&D expenses for the consolidated fiscal year was ¥99 million.」
The Company continued R&D on cost reduction through a new production method, effects in improving the intestinal environment and new functionality, and new products, while R&D expenses amounted to ¥99 million. - FY2019-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥75 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
The Company continues its research and development activities and states that there have been no material changes in their status. - FY2019-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥49 million. There were no material changes in the status of the Group's research and development activities during the six-month consolidated cumulative period.」
The Company continues its research and development activities and states that there have been no material changes in their status. - FY2019-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥25 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
The company stated that it continued its research and development activities and that there were no material changes in their status. - FY2018Research themes became more specific and R&D spending increasedAnnual report
「The Company mainly conducted research on evaluating the immune function of galacto-oligosaccharide, which selectively increases bifidobacteria, in connection with the much-discussed gut microbiome, as well as developing a new production method to reduce costs. The total amount of R&D expenses for the consolidated fiscal year was ¥96 million.」
The R&D themes were specified as evaluating immune function and developing a new production method, and R&D expenses amounted to ¥96 million. - FY2018-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥71 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
The Company continues its research and development activities and states that there have been no material changes in their status. - FY2018-Q2RestatedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥48 million. There were no material changes in the status of the Group's research and development activities during the six-month consolidated cumulative period.」
The Company continues its research and development activities and states that there have been no material changes in their status. - FY2018-Q1RestatedAnnual report
「The total amount of the Group's research and development activities during the three-month consolidated cumulative period was ¥23 million. There were no material changes in the status of the Group's research and development activities during the three-month consolidated cumulative period.」
The Company continues its research and development activities and states that there have been no material changes in their status. - FY2017-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the nine-month consolidated cumulative period was ¥68 million. There were no material changes in the status of the Group's research and development activities during the nine-month consolidated cumulative period.」
Research and development spending continued, and it was stated that there were no material changes in the status of research and development activities. - FY2017-Q2First statedAnnual report
「The total amount of the Group's research and development activities during the six-month consolidated cumulative period was ¥47 million.」
The total amount of research and development activities during the six-month cumulative period was stated as ¥47 million.